KLRA

Kailera Therapeutics Inc

10.84

Oct 05 • 2:39 PM ET +0.45 (4.33%)

Healthcare Biotechnology USA Small NASD

Oct 01, 6:50 AMKailera reports new Phase 1 data for ribupatide and KAI-4729 showing strong weight loss and liver fat reductions with no new safety signals

Peers: VKTX NAMS MDGL RYTM BMRN KRYS AXSM INCY KROS NBIX

| Held by: VTI XBI VB IWM VBK VXF VTWO IWO OZEM SCHA

Scroll to Statements

Index	RUT
Market Cap	1.41B
Enterprise Value	498.82M
Income	-
Sales	-
Book/sh	8.63
Cash/sh	7.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	145
IPO	Apr 17, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.26
P/C	1.53
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.11
Current Ratio	11.11
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-
EPS next Y	-4.30
EPS next Q	-1.01
EPS this Y	-202.70%
EPS next Y	-2.10%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	-21.56% -

Insider Own	56.26%
Insider Trans	38.89%
Inst Own	44.00%
Inst Trans	79.68%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-14.19%
SMA50	-30.30%
SMA200	-42.77%
Trades

Shs Outstand	129.62M
Shs Float	56.71M
Short Float	10.51%
Short Ratio	7.22
Short Interest	5.96M
52W High	28.23 -61.60%
52W Low	10.29 5.34%
Volatility	7.59% 7.46%
ATR (14)	1.02
RSI (14)	32.32
Beta	-
Rel Volume	1.40
Avg Volume	826.06K
Volume	927,721

Perf Week	-2.52%
Perf Month	-31.13%
Perf Quarter	-51.26%
Perf Half Y	-
Perf YTD	-58.31%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	42.75
Prev Close	10.39
Price	10.84
Change %	4.33%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-26	Initiated	William Blair	Outperform
May-12-26	Initiated	TD Cowen	Buy	$57
May-12-26	Initiated	Leerink Partners	Outperform	$36
May-12-26	Initiated	JP Morgan	Overweight	$30
May-12-26	Initiated	Jefferies	Buy	$48
May-12-26	Initiated	Evercore ISI	Outperform

Oct-01-26 06:45AM	Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting (GlobeNewswire)
Sep-30-26 07:00AM	Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection (GlobeNewswire)
Sep-16-26 07:00AM	Kailera Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -5.58%
Aug-12-26 04:05PM	Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-11-26 07:00AM	Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer (GlobeNewswire)
10:10AM	Loading…
Jul-08-26 10:10AM	Kailera weight loss pill trial results: Nausea sinks stock (Quartz)
Jul-07-26 01:19PM	Eli Lilly's Market Cap Balloons Again On This IPO's Setback (Investor's Business Daily)
07:59AM	Kailera says obesity pill succeeds in late-stage trial in China (BioPharma Dive)
07:00AM	Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 (GlobeNewswire)
Jun-29-26 07:30AM	Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer (GlobeNewswire)
Jun-18-26 12:56PM	Kardigan rises in Nasdaq debut after upsized $400 million IPO (Reuters)
Jun-15-26 12:48AM	I worry deeply about bioterrorism: Is Europe sufficiently prepared for another pandemic? (Euronews)
Jun-10-26 12:21PM	Cancer drug startup Parabilis Medicines is raising a record $670 million in its IPO (Quartz)
07:06AM	Parabilis sets a record with a $670M biotech IPO (BioPharma Dive)
Jun-05-26 07:32PM	Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026 (GlobeNewswire) -7.72%
04:05PM	Loading…
May-28-26 04:05PM	Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-26-26 04:02PM	Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates (GlobeNewswire)
May-13-26 07:30AM	Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire) -5.34%
May-12-26 12:50PM	Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity (Investor's Business Daily)
Apr-20-26 04:05PM	Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.35%

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.

M.B.A.Mr. Ronald C. Renaud Jr.

M.S.Mr. Paul Douglas Burgess J.D.

Chief Commercial OfficerMs. Jamie Beth Coleman

Chief Financial OfficerMr. Douglas W. Pagan M.B.A.

Vice President of Corporate Communications & Investor RelationsMaura Gavaghan

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Renaud Ronald C JR	CEO & President	Jun 09 '26	Option Exercise	5.25	38,094	199,994	38,094	Jun 11 04:05 PM
RTW INVESTMENTS, LP	10% Owner	Apr 20 '26	Buy	16.00	500,000	8,000,000	10,776,820	Apr 22 04:15 PM
BAIN CAPITAL INVESTORS LLC	10% Owner	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:10 PM
Koppel Adam	Director	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:08 PM
Bain Capital Life Sciences Inv	10% Owner	Apr 20 '26	Buy	16.00	1,562,500	25,000,000	22,583,268	Apr 20 06:01 PM
Kaplan Andrew T.	Director	Apr 20 '26	Buy	16.00	8,398,438	134,375,008	26,255,581	Apr 20 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KLRA

Kailera Therapeutics Inc

Upgrade your Finviz experience